Research has found that weight-loss drugs such as Ozempic may help curb addictive behaviours, such as alcohol addiction. One ...

A once-weekly dose of tirzepatide (Mounjaro) can lead to significant, sustained weight loss for up to 3 years in adults with ...

Long-term use of tirzepatide shows sustained and significant weight loss in adults with overweight or obesity.

Orforglipron, which could become the first GLP-1 pill — a much more convenient option — is a step closer to hitting the ...

New research being presented at this year's European Congress on Obesity (ECO 2025, Malaga, Spain, 11–14 May) shows that ...

Orforglipron, a once-daily glucagon-like peptide-1 (GLP-1) receptor agonist, significantly reduced hemoglobin A1c (HbA1c) in adults with type 2 diabetes (T2D) and inadequate glycemic control with diet ...

A new international study reveals a possible connection between GLP1 receptor agonists—used in drugs like Ozempic—and ...

Both glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) are ...

Oral semaglutide cuts major heart risks in people with type 2 diabetes by 14%, offering a powerful pill-based option. Both ...

A groundbreaking study published in the journal Current Neuropharmacology highlights a concerning potential link between Glucagon-like Peptide-1 (GLP1) receptor agonists-widely used in blockbuster ...

A new oral GLP-1 drug candidate could transform the diabetes and weight loss drug boom. Why it matters: Eli Lilly said on ...

Lilly's weight-loss drug trial shows promising results, propelling stock up 14.36%. Goldman Sachs predicts potential $23.5B in sales by 2035.